Immunohistochemical features and EBV status of tumor cells
| Tumor cell–associated marker . | AR-DLBCL total . | AR-DLBCL pre-HAART era . | AR-DLBCL HAART era . | Sporadic DLBCL . |
|---|---|---|---|---|
| CD20 positive, % (no./total) | 80.5 (33/41) | 83.3 (10/12) | 79.3 (23/29) | 94.34 (50/53) |
| GC phenotype, % (no./total) | 46.34 (19/41) | 41.67 (5/12) | 48.28 (14/29) | 33.96 (18/53) |
| Non-GC phenotype, % (no./total) | 46.34 (19/41) | 33.33 (4/12) | 51.7 (15/29) | 52.8 (28/53) |
| Unclassifiable phenotype, % (no./total) | 7.3 (3/41) | 25 (3/12) | 0 (0/29) | 13.2 (7/53) |
| Bcl-2 positive, % (no./total) | 43.9 (18/41) | 16.7 (2/12) | 55.2 (16/29) | 58.5 (31/53) |
| Median Ki67, % (range, %) | 85 (40-95) | 78.75 (50-90) | 85 (40-95) | 70 (35-92.5) |
| Ki67 > 80%, % (no./total) | 54.55 (18/33) | 50 (4/8) | 56 (14/25) | 13.2 (7/53) |
| CD5 positive, % (no./total) | 8.82 (3/34) | 0 (0/7) | 11.11 (3/27) | 8.82 (3/34) |
| EBER positive, % (no./total) | 56.1 (23/41) | 91.7 (11/12) | 41.7 (12/29) | 5.7 (3/53) |
| Tumor cell–associated marker . | AR-DLBCL total . | AR-DLBCL pre-HAART era . | AR-DLBCL HAART era . | Sporadic DLBCL . |
|---|---|---|---|---|
| CD20 positive, % (no./total) | 80.5 (33/41) | 83.3 (10/12) | 79.3 (23/29) | 94.34 (50/53) |
| GC phenotype, % (no./total) | 46.34 (19/41) | 41.67 (5/12) | 48.28 (14/29) | 33.96 (18/53) |
| Non-GC phenotype, % (no./total) | 46.34 (19/41) | 33.33 (4/12) | 51.7 (15/29) | 52.8 (28/53) |
| Unclassifiable phenotype, % (no./total) | 7.3 (3/41) | 25 (3/12) | 0 (0/29) | 13.2 (7/53) |
| Bcl-2 positive, % (no./total) | 43.9 (18/41) | 16.7 (2/12) | 55.2 (16/29) | 58.5 (31/53) |
| Median Ki67, % (range, %) | 85 (40-95) | 78.75 (50-90) | 85 (40-95) | 70 (35-92.5) |
| Ki67 > 80%, % (no./total) | 54.55 (18/33) | 50 (4/8) | 56 (14/25) | 13.2 (7/53) |
| CD5 positive, % (no./total) | 8.82 (3/34) | 0 (0/7) | 11.11 (3/27) | 8.82 (3/34) |
| EBER positive, % (no./total) | 56.1 (23/41) | 91.7 (11/12) | 41.7 (12/29) | 5.7 (3/53) |